DK0522091T5 - Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose - Google Patents

Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose

Info

Publication number
DK0522091T5
DK0522091T5 DK91910085T DK91910085T DK0522091T5 DK 0522091 T5 DK0522091 T5 DK 0522091T5 DK 91910085 T DK91910085 T DK 91910085T DK 91910085 T DK91910085 T DK 91910085T DK 0522091 T5 DK0522091 T5 DK 0522091T5
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
directed
medication
preparation
treatment
Prior art date
Application number
DK91910085T
Other languages
Danish (da)
English (en)
Other versions
DK0522091T3 (da
Inventor
Howard L Weiner
David Allen Hafler
Kai W Wucherpfenning
Original Assignee
Brigham & Womens Hospital
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Autoimmune Inc filed Critical Brigham & Womens Hospital
Publication of DK0522091T3 publication Critical patent/DK0522091T3/da
Application granted granted Critical
Publication of DK0522091T5 publication Critical patent/DK0522091T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
DK91910085T 1990-03-30 1991-03-29 Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose DK0522091T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50255990A 1990-03-30 1990-03-30
PCT/US1991/002218 WO1991015225A1 (en) 1990-03-30 1991-03-29 Multiple sclerosis t-cell receptor

Publications (2)

Publication Number Publication Date
DK0522091T3 DK0522091T3 (da) 2002-04-08
DK0522091T5 true DK0522091T5 (da) 2008-06-23

Family

ID=23998362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910085T DK0522091T5 (da) 1990-03-30 1991-03-29 Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose

Country Status (13)

Country Link
EP (1) EP0522091B9 (de)
JP (1) JPH05507911A (de)
AT (1) ATE210721T1 (de)
AU (1) AU651350B2 (de)
BR (1) BR9106303A (de)
CA (1) CA2078549C (de)
DE (1) DE69132863T2 (de)
DK (1) DK0522091T5 (de)
ES (1) ES2169021T3 (de)
HU (1) HU217847B (de)
IL (3) IL165071A (de)
NO (1) NO308611B1 (de)
WO (1) WO1991015225A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
EP0527199B2 (de) * 1990-05-01 2000-08-30 The Board Of Trustees Of The Leland Stanford Junior University Stoffgemische zur Anwendung in einem Verfahren zur Behandlung eines an multipler Sklerose leidenden Menschen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1992012996A2 (en) * 1991-01-22 1992-08-06 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2126686A1 (en) * 1991-12-24 1993-07-08 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
AU2950195A (en) * 1994-07-01 1996-01-25 Connective Therapeutics Inc. Methods for diagnosing an immune-related disease and choosing an immune-related therapy
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
JP4986361B2 (ja) 2000-05-24 2012-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｅ−セレクチンに対する寛容誘導による脳卒中防止法
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
NZ537403A (en) * 2002-06-05 2009-10-30 Baylor College Medicine T cell receptor CDR3 sequences and methods for detection
US7744893B2 (en) 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
NZ537816A (en) 2002-08-08 2007-06-29 Baylor College Medicine An autologous T cell vaccine for the treatment of multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases

Also Published As

Publication number Publication date
IL165071A0 (en) 2005-12-18
EP0522091B9 (de) 2007-11-21
ATE210721T1 (de) 2001-12-15
IL97709A (en) 2005-05-17
WO1991015225A1 (en) 1991-10-17
NO308611B1 (no) 2000-10-02
DE69132863D1 (de) 2002-01-24
NO923778L (no) 1992-11-16
HU217847B (hu) 2000-04-28
AU651350B2 (en) 1994-07-21
DK0522091T3 (da) 2002-04-08
JPH05507911A (ja) 1993-11-11
CA2078549C (en) 2006-07-11
NO923778D0 (no) 1992-09-29
CA2078549A1 (en) 1991-10-01
EP0522091B1 (de) 2001-12-12
EP0522091A1 (de) 1993-01-13
IL165071A (en) 2008-06-05
AU7898991A (en) 1991-10-30
HU9203100D0 (en) 1992-12-28
ES2169021T3 (es) 2002-07-01
DE69132863T2 (de) 2002-06-20
BR9106303A (pt) 1993-04-13
EP0522091A4 (en) 1993-05-26
HUT63334A (en) 1993-08-30
IL97709A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
DK0522091T5 (da) Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose
GB2255093A (en) Hiv-1 core protein fragments
ATE120093T1 (de) Meningococcales klasse i-aussenmembranprotein- vakzin.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
AU4201197A (en) An immunological method for detecting antibodies directed against tissue transglutaminase (TTG), use of TTG in diagnosis and therapy control, and an oral pharmaceutical agent containing TTG
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
ATE243750T1 (de) Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
DK101888A (da) Immunmodulerende midler og anvendelse af disse
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
DK0601108T3 (da) Multideterminante peptidantigener, som stimulerer T-hjælpelymfocytrespons til HIV hos en gruppe mennesker
NZ515332A (en) Lawsonia derived gene and related SodC polypeptides, peptides and proteins and their uses
FI924215A0 (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
HUP0003164A2 (hu) A Helicobacter pylori FlgE polipeptidet tartalmazó vakcinakészítmények
DE69322960D1 (de) Empfängnisverhütender impfstoff
张津利 et al. Preliminary study of immunodiagnosis of trichinosis by ELISA using urea-soluble antigen of Trichinella spiralis
Zhang Study of protective effect of outer membrane proteins of Vibrio cholerae with monoclonal antibodies.
FI963331A (fi) Dermatophagoidesista (huonepölypunkeista) peräisin olevien pääasiallisten allergeenien T-soluepitoopit